Core Insights - Lexaria Bioscience Corp. has successfully completed a human study comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide, with partial results now available [1][8] - The study demonstrated a 22.7% reduction in adverse events (AEs) for oral DehydraTECH-liraglutide compared to Saxenda®, with significant reductions in nausea (67%) and gastrointestinal AEs (31%) [3][4] - Lexaria is seeking a pharmaceutical partner to develop an FDA-registered oral alternative to current injectable GLP-1 drugs, addressing an unmet market need [2][10] Study Details - The study involved 10 overweight volunteers, comparing daily doses of Saxenda® (0.6 mg) and DehydraTECH-liraglutide (45 mg) over a 7-day period [13] - The primary endpoint was the evaluation of safety and tolerability, with secondary objectives including pharmacokinetics and effects on body weight, blood glucose, and insulin levels [16] - Weight loss was observed in 9 out of 10 participants in both study arms, although it was not the primary goal of the study [5] Technology and Market Context - DehydraTECH is a patented drug delivery technology that enhances bio-absorption and reduces side effects, with 48 patents granted and more pending [17] - The study's results suggest that DehydraTECH-liraglutide could provide a viable oral alternative to Saxenda® and other injectable liraglutide products, which generated significant revenue for Novo Nordisk [12] - Lexaria's approach may allow for an expedited FDA regulatory pathway under the 505(b)(2) application, contingent on demonstrating comparable performance to existing injectable versions [6][10]

Following the company's first-quarter earnings report, shares of Hims & Hers Health (HIMS 5.21%) opened the following day considerably lower, only to sprint higher once trading began. This action is just one example of why the stock is a bit of a divisive name among investors. This can also be seen in its high short interest, which sits above 25%.The stock is up around 108% year to date (as of this writing), while at the same time it's down about 27% from the highs it set earlier this year. Let's take a clo ...

Hims & Hers Health (HIMS) Q1 2025 Earnings Call May 05, 2025 05:00 PM ET Company Participants Bill Newby - Senior Director, Investor RelationsAndrew Dudum - Co-Founder & Chief Executive OfficerYemi Okupe - Chief Financial OfficerJonna Kim - DirectorDavid Larsen - Managing Director Conference Call Participants Craig Hettenbach - AnalystMaria Ripps - Managing Director, Senior Research AnalystEric Percher - Research Analyst - Pharma Supply Chain and HCITRyan Macdonald - Senior AnalystDaniel Grosslight - Senior ...

Hims & Hers Health (HIMS) Q1 2025 Earnings Call May 05, 2025 05:00 PM ET Speaker0 Good afternoon, ladies and gentlemen. Thank you for standing by. At this time, I would like to welcome everyone to the Speaker1 Hims Hens and Hers Health first quarter twenty twenty five earnings call. Today, after the market closed, we released this quarter's shareholder letter, a copy of which you can find on our website at investors.hens.com. On the call with me today is Andrew Dudum, our Co Founder and Chief Executive Offi ...

Core Insights - Novo Nordisk is expanding access to its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro, and Life MD, as supply shortages have eased in the U.S. [1][2] - Hims & Hers shares surged 40% in premarket trading, while Novo Nordisk's stock rose 3% following the announcement [2]. Company Strategies - Novo Nordisk aims to capture more patients by collaborating with telehealth companies, as compounding pharmacies face legal restrictions on producing cheaper, unapproved versions of Wegovy [2][3]. - The partnerships with telehealth providers are designed to create a seamless experience for patients, allowing them to access Wegovy directly from their providers [4]. Pricing and Accessibility - Wegovy will be offered at $499 per month through Novo Nordisk's direct-to-consumer online pharmacy, which is about half of its usual list price for uninsured patients [5]. - Hims & Hers will provide Wegovy starting at $599 per month, which includes additional services such as 24/7 care and nutritional guidance [5][6]. Market Context - Hims & Hers has previously offered compounded versions of semaglutide but is now transitioning to the branded Wegovy due to regulatory changes [9]. - The FDA has set deadlines for compounding pharmacies to cease the production of unapproved versions of semaglutide, impacting the availability of alternatives [10].